GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » Cyclically Adjusted Price-to-FCF

Nektar Therapeutics (FRA:ITH) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted Price-to-FCF Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Nektar Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Nektar Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Nektar Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.227/131.7762*131.7762
=-0.227

Current CPI (Mar. 2024) = 131.7762.

Nektar Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.057 100.560 -0.075
201409 -0.275 100.428 -0.361
201412 -0.179 99.070 -0.238
201503 0.424 99.621 0.561
201506 -0.344 100.684 -0.450
201509 -0.122 100.392 -0.160
201512 -0.531 99.792 -0.701
201603 -0.167 100.470 -0.219
201606 -0.099 101.688 -0.128
201609 -0.181 101.861 -0.234
201612 -0.350 101.863 -0.453
201703 -0.235 102.862 -0.301
201706 -0.348 103.349 -0.444
201709 0.475 104.136 0.601
201712 -0.442 104.011 -0.560
201803 -0.269 105.290 -0.337
201806 4.493 106.317 5.569
201809 -0.363 106.507 -0.449
201812 -0.611 105.998 -0.760
201903 -0.441 107.251 -0.542
201906 -0.332 108.070 -0.405
201909 -0.383 108.329 -0.466
201912 -0.659 108.420 -0.801
202003 -0.403 108.902 -0.488
202006 -0.431 108.767 -0.522
202009 -0.259 109.815 -0.311
202012 -0.459 109.897 -0.550
202103 -0.370 111.754 -0.436
202106 -0.392 114.631 -0.451
202109 -0.480 115.734 -0.547
202112 -0.753 117.630 -0.844
202203 -0.453 121.301 -0.492
202206 -0.384 125.017 -0.405
202209 -0.447 125.227 -0.470
202212 -0.292 125.222 -0.307
202303 -0.259 127.348 -0.268
202306 -0.252 128.729 -0.258
202309 -0.207 129.860 -0.210
202312 -0.227 129.419 -0.231
202403 -0.227 131.776 -0.227

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (FRA:ITH) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Nektar Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics (FRA:ITH) Business Description

Industry
Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines